THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms | Zendy

Maria Trojano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms

Author(s) -

Maria Trojano

Publication year - 2016

Publication title -

european neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.573

H-Index - 77

eISSN - 1421-9913

pISSN - 0014-3022

DOI - 10.1159/000444235

Subject(s) - medicine , interim analysis , observational study , randomized controlled trial , context (archaeology) , clinical trial , adverse effect , cannabis , physical therapy , spasticity , psychiatry , paleontology , biology

The prospective observational MObility ImproVEment (MOVE) 2 study is collecting real-life clinical outcomes data on patients with treatment-resistant multiple sclerosis (MS) spasticity treated with THC:CBD oromucosal spray in routine clinical practice. The MOVE 2 study has been ongoing in Italy, involving more than 30 MS centres across the country, since 2013.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research